ARS Pharmaceuticals Announces Board Resignation and CMO Departure

What Happened
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K reporting that on July 15, 2026 Richard Lowenthal resigned from the Board of Directors effective immediately. That resignation was a condition of his eligibility to receive severance under his employment agreement and the Company’s Change in Control and Severance Benefit Plan (see the April 29, 2026 Proxy Statement). On the same date, Sarina Tanimoto, M.D., the Company’s Chief Medical Officer, ceased employment in a termination without cause. The Company agreed to make additional one‑time payments representing prorated 2026 target bonuses to each executive.

Key Details

• Date of events: July 15, 2026 (resignation and termination effective immediately).
• Board member: Richard Lowenthal resigned; CMO: Sarina Tanimoto, M.D., ceased employment.
• One-time prorated bonus payments: $217,350 to Mr. Lowenthal and $111,780 to Dr. Tanimoto (total $329,130).
• Payments and severance described in the Proxy Statement are conditioned on the effectiveness of a release of claims by each executive.

Why It Matters
This filing documents an immediate governance change (a Board member departure) and the loss of the company’s CMO, which may affect management continuity and clinical/program leadership. It also commits the company to additional cash outlays (the stated prorated bonuses plus whatever severance is due under existing agreements), though those payments are conditioned on signed releases. Investors should note the personnel change and potential cash impact, and watch for any further disclosures about replacement directors or clinical leadership.